Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.
NCT04178057
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Brain Tumor
Interventions
BIOLOGICAL:
GB222 3mg/kg
BIOLOGICAL:
GB222 5mg/kg
BIOLOGICAL:
GB222 7.5mg/kg
BIOLOGICAL:
GB222 10mg/kg
Sponsor
Genor Biopharma Co., Ltd.